Andrew Burch
Equibles does not estimate personal net worth.
About Andrew Burch
Maravai Lifesciences Holdings, Inc. reported in an 8-K filed January 8, 2025 that Andrew Burch was terminated as President, Nucleic Acid Production, effective January 16, 2025. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed March 13, 2023 that Andrew Burch was appointed Executive Vice President and General Manager of the Company's Nucleic Acid Products Operating Division, effective March 31, 2023. The proxy statement of Maravai Lifesciences Holdings, Inc. reports total compensation of $2,558,244 for Andrew Burch in fiscal 2024, including a base salary of $472,583. Disclosed compensation is on record for 2 fiscal years.
“On January 2, 2025, the Company notified Andrew Burch, President, Nucleic Acid Production, that it was eliminating his position in order to flatten the organizational structure of its leadership team.”
“Andrew Burch, previously an executive at Thermo Fisher Scientific, has joined the Company and will assume the role of Executive Vice President and General Manager of the Company's Nucleic Acid Products Operating Division following Mr. Neel's departure on March 31st.”
Affiliation history
-
Maravai Lifesciences Holdings, Inc. (MRVI)
Proxy statement
2023-03-31–2025-01-16
-
Maravai Lifesciences Holdings, Inc. (MRVI)
Proxy statement
Start not stated–2025-04-18
Last confirmed by a filing; no departure on record
-
Maravai Lifesciences Holdings, Inc. (MRVI)
Proxy statement
Start not stated–2025-01-16
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Maravai Lifesciences Holdings, Inc. (MRVI) | Former President, Nucleic Acid Production | $472,583 | $2,558,244 |
| 2023 | Maravai Lifesciences Holdings, Inc. (MRVI) | Former President, Nucleic Acid Production | $371,539 | $2,992,807 |